BACKGROUND: Group A streptococcus (GAS) pharyngitis is associated with high rates of rheumatic heart disease in developing countries. We sought to identify guidelines for empiric treatment of pharyngitis in low-resource settings. To inform the design of GAS vaccines, we determined the emm types associated with pharyngitis among African schoolchildren. METHODS: Surveillance for pharyngitis was conducted among children 5-16 years of age attending schools in Bamako, Mali. Students were encouraged to visit a study clinician when they had a sore throat. Enrollees underwent evaluation and throat swab for isolation of GAS. Strains were emm typed by standard methods. RESULTS: GAS was isolated from 449 (25.5%) of the 1,759 sore throat episodes. Painful cervical adenopathy was identified in 403 children (89.8%) with GAS infection and was absent in 369 uninfected children (28.2%). Emm type was determined in 396 (88.2%) of the 449 culture-positive children; 70 types were represented and 14 types accounted for 49% of isolates. Based on the proportion of the 449 isolates bearing emm types included in the 30-valent vaccine (31.0%) plus nonvaccine types previously shown to react to vaccine-induced bactericidal antibodies (44.1%), the vaccine could protect against almost 75% of GAS infections among Bamako schoolchildren. CONCLUSIONS: Two promising strategies could reduce rheumatic heart disease in low-resource settings. Administering antibiotics to children with sore throat and tender cervical adenopathy could treat most GAS-positive children while reducing use of unnecessary antibiotics for uninfected children. Broad coverage against M types associated with pharyngitis in Bamako schoolchildren might be achieved with the 30-valent GAS vaccine under development.
BACKGROUND:Group A streptococcus (GAS) pharyngitis is associated with high rates of rheumatic heart disease in developing countries. We sought to identify guidelines for empiric treatment of pharyngitis in low-resource settings. To inform the design of GAS vaccines, we determined the emm types associated with pharyngitis among African schoolchildren. METHODS: Surveillance for pharyngitis was conducted among children 5-16 years of age attending schools in Bamako, Mali. Students were encouraged to visit a study clinician when they had a sore throat. Enrollees underwent evaluation and throat swab for isolation of GAS. Strains were emm typed by standard methods. RESULTS:GAS was isolated from 449 (25.5%) of the 1,759 sore throat episodes. Painful cervical adenopathy was identified in 403 children (89.8%) with GAS infection and was absent in 369 uninfected children (28.2%). Emm type was determined in 396 (88.2%) of the 449 culture-positive children; 70 types were represented and 14 types accounted for 49% of isolates. Based on the proportion of the 449 isolates bearing emm types included in the 30-valent vaccine (31.0%) plus nonvaccine types previously shown to react to vaccine-induced bactericidal antibodies (44.1%), the vaccine could protect against almost 75% of GAS infections among Bamako schoolchildren. CONCLUSIONS: Two promising strategies could reduce rheumatic heart disease in low-resource settings. Administering antibiotics to children with sore throat and tender cervical adenopathy could treat most GAS-positive children while reducing use of unnecessary antibiotics for uninfected children. Broad coverage against M types associated with pharyngitis in Bamako schoolchildren might be achieved with the 30-valent GAS vaccine under development.
Authors: Lonnie J Miner; Susan J Petheram; Judy A Daly; E Kent Korgenski; Kristie S Selin; Sean D Firth; L George Veasy; Harry R Hill; James F Bale Journal: Pediatr Infect Dis J Date: 2004-01 Impact factor: 2.129
Authors: L George Veasy; Lloyd Y Tani; Judy A Daly; Kent Korgenski; Lonnie Miner; James Bale; Edward L Kaplan; James M Musser; Harry R Hill Journal: Pediatrics Date: 2004-03 Impact factor: 7.124
Authors: Karen L Kotloff; Mary Corretti; Kathleen Palmer; James D Campbell; Mark A Reddish; Mary C Hu; Steven S Wasserman; James B Dale Journal: JAMA Date: 2004-08-11 Impact factor: 56.272
Authors: F Koutouzi; A Tsakris; P Chatzichristou; E Koutouzis; G L Daikos; E Kirikou; N Petropoulou; V Syriopoulou; A Michos Journal: J Clin Microbiol Date: 2015-04-15 Impact factor: 5.948
Authors: James B Dale; Pierre R Smeesters; Harry S Courtney; Thomas A Penfound; Claudia M Hohn; Jeremy C Smith; Jerome Y Baudry Journal: Vaccine Date: 2016-11-24 Impact factor: 3.641
Authors: Dylan D Barth; Mark E Engel; Andrew Whitelaw; Alemseged Abdissa; Wilson E Sadoh; Sulafa K M Ali; Samba O Sow; James Dale; Bongani M Mayosi Journal: BMJ Open Date: 2016-02-25 Impact factor: 2.692
Authors: John Musuku; Joyce C Lungu; Elizabeth Machila; Catherine Jones; Laurence Colin; Sherri Schwaninger; Patrick Musonda; Brigitta Tadmor; Jonathan M Spector; Mark E Engel; Liesl J Zühlke Journal: BMC Infect Dis Date: 2017-07-06 Impact factor: 3.090